Tanaka-Kataoka M, Kunikata T, Takayama S, Iwaki K, Fujii M, Ohashi K, Ikeda M, Kurimoto M
Fujisaki Institute, Hayashibara Biochemical Labs., Inc., Okayama, Japan.
J Interferon Cytokine Res. 1999 Aug;19(8):877-9. doi: 10.1089/107999099313398.
Insulin-dependent diabetes mellitus (IDDM) in the nonobese diabetes (NOD) mouse model is thought to be an autoimmune CD4 Th1-like cell-mediated disease. We tested the efficacy of oral use of interferon-alpha (IFN-alpha) therapy on IDDM in NOD mice. Using urine and blood sugar levels as indicators of IDDM, oral administration of murine IFN-alpha (100 IU/body) to NOD mice significantly delayed the onset of symptomatic diabetes. However, oral use of IFN-alpha did not prevent diabetic NOD mice from losing weight once NOD mice were symptomatic, suggesting that orally administered IFN-alpha is a prophylactic rather than therapeutic approach to the management of IDDM.
非肥胖型糖尿病（NOD）小鼠模型中的胰岛素依赖型糖尿病（IDDM）被认为是一种自身免疫性CD4 Th1样细胞介导的疾病。我们测试了口服干扰素-α（IFN-α）治疗NOD小鼠IDDM的疗效。以尿糖和血糖水平作为IDDM的指标，给NOD小鼠口服鼠源IFN-α（100 IU/只）可显著延迟症状性糖尿病的发病。然而，一旦NOD小鼠出现症状，口服IFN-α并不能阻止糖尿病NOD小鼠体重减轻，这表明口服IFN-α是一种预防而非治疗IDDM的方法。
